April 14 (Reuters) - IDEAYA Biosciences Inc IDYA.O:
IDEAYA BIOSCIENCES ANNOUNCES SUCCESSFUL FDA TYPE D MEETING ON PHASE 3 REGISTRATIONAL TRIAL DESIGN FOR DAROVASERTIB AS NEOADJUVANT THERAPY FOR PRIMARY UVEAL MELANOMA
IDEAYA BIOSCIENCES-TARGETING TO INITIATE PHASE 3 RANDOMIZED REGISTRATIONAL TRIAL FOR DAROVASERTIB IN NEOADJUVANT SETTING IN PRIMARY UM IN H1 2025
Source text: ID:nPn51pd8ba
Further company coverage: IDYA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.